Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

Sustol

granisetron
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Sancuso FILM, EXTENDED RELEASE, TRANSDERMAL 3.1 mg/24 hr      
Kytril SOLUTION, INTRAVENOUS 1 mg/mL      
Sustol SUSPENSION, EXTENDED RELEASE, INJECTABLE 10 mg/0.4 mL    
Kytril TABLET, ORAL 1 mg      
VIEW MORE 5-HT3 Receptor Antagonists
CLASS
562220
Comments:

Ordered Formulation

Therapeutic Interchange

granisetron (Sustol)

  • 10 mg extended release subQ on day 1 of chemotherapy, then once every 7 days

ondansetron (Zofran)

  • 16 mg IV or PO

Sustol injection medication guide

Sustol is non-formulary. Interchange to ondansetron oral tablets or intravenous injection. 16 mg dose x 1 dose at each dose of chemotherapy. Reviewed by Oncology subcommittee. 

Sancuso Patch is non-formulary, not stocked. If ordered for an inpatient, contact the physician and have changed to a formulary agent. If a patient is admitted with a patch that had been applied as an outpatient, the patch should be discontinued and the physician should be notified.

Reviewed: December 16, 2009 (Sancuso Patch) and 28 Feb 2017 (Sustol)

Last updated: Dec. 26, 2017






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved